$CLN #Celon Pharma SA Celon Pharma: PDE10a inhibitor - soon in the phase II; rNPV of the project = PLN 3.3 per share: Celon Pharma: PDE10a inhibitor - soon in the phase II; rNPV of the project = PLN 3.3 per share – Ad hoc report,… https://t.co/VixbsubdmD #equity #stocks https://t.co/4VHT7LtdHT